Daily Dose - Apr 24th, 2024
 
 
Daily Dose | View online
 
April 24, 2024
Leading pharma teams are looking to artificial intelligence-based technologies to automate processes, improve efficiency and ensure accurate reporting. One of these notable technologies is natural language processing (NLP), which uses algorithms to ‘read’ through unstructured text, then transform it into structured data that is suitable for analysis and visualization.
Anktiva is the first IL-15 superagonist approved for non-muscle invasive bladder cancer.
Led by Genentech's former Chief Scientific Officer, Xaira is betting on the application of computational methods to drug design.
The radioligand therapy is the first FDA approved treatment specifically for children with gastroenteropancreatic neuroendocrine tumors.
Sponsored
mRNA-LNP manufacturing is fraught with obstacles, resulting in higher program risk, inflated costs, and delayed market release. With the right knowledge, companies can overcome the challenges to de-risk & optimize the path to manufacturing success.